Compare Citius Pharmaceuticals Inc (CTXR) vs SiTime Corporation (SITM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs SiTime Corporation — how do they compare? Citius Pharmaceuticals Inc trades at $0.53 (market cap $14.64M), while SiTime Corporation trades at $630.25 (market cap $18.72B). The key difference: SiTime Corporation is far larger — about 1278.7× Citius Pharmaceuticals Inc's market cap, and SiTime Corporation is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | SITM | |
|---|---|---|
Market Cap | $14.64M | $18.72B |
Sector | Health | Technology |
52-Week High | $1.82 | $901.60 |
52-Week Low | $0.53 | $190.16 |
Enterprise Value | $10.86M | $17.93B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
SITM trades at $602.55, down 4.2% over 24 hours, with a bearish technical signal despite recent earnings beats. The company shows strong revenue growth and expanding gross margins, driven by AI infrastructure demand and the completed Renesas acquisition. Analyst consensus remains unanimously bullish with a $743.75 price target, though negative net income and high valuation ratios present fundamental concerns.
Outlook is mixed: robust AI-driven growth and strategic acquisitions offer upside, but profitability challenges and bearish technicals near-term pose risks. Investors should weigh strong analyst support against cash flow volatility and execution risks in integrating new assets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About SiTime Corporation
SiTime Corporation is a leading provider of MEMS-based silicon timing solutions used in various electronic applications. The company’s products, including oscillators, resonators, and clock ICs, are designed to replace traditional quartz-based timing devices, offering superior performance, reliability, and smaller size in harsh environments. SiTime's solutions are adopted across high-growth markets such as 5G, data centers, industrial IoT, and automotive, positioning the company as a key enabler for next-generation electronic systems.
Read more on SITM →
